Is radical prostatectomy primarily a surgical debulking procedure?

Urologic Oncology

Volumn 2, Issue 3, 1996, Pages 88-91

  Badalament, Robert A ^a,b   Bahn, Duke K ^a   Lee, Fred ^a  

^a Crittenton Hospital Medical Center   (United States)

^b NONE   (United States)

Author keywords

Prostate cancer; prostate specific antigen; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER SIZE; CANCER SURVIVAL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT INDICATION;

EID: 0030135522     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(96)00062-2     Document Type: Article

References (24)

1. 1. McNeal JE, Kindrachuk RA, Freiha FS, Bostwick DG, Redwine EA, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;1:60-3.
2. 2. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatecotomies. J Urol 1988;139:1235-41.
3. 3. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: Relationship to local and distant spread. Hum Pathol 1992;23:258-66.
4. 4. Babaian RJ, Troncoso P, Steelhammer LC, Lloretta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability. J Urol 1995;154:1808-12.
5. 5. Stamey TA, Freiha FS, McNeal JE, Redwine E, Whittemore AS, Schmid H-P. Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
6. 6. Epstein JI, Walsh PC, Carmichael M, Brendler CBL. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:268-74.
7. 7. Dugan JA, Bostwick DG, Myers RP, Quian J, Bergstralh MS, Oesterling J. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-94.
8. 8. Terris MK, Haney DJ, Johnstome IM, McNeal JE, Stamey TA. Prediction of prostate cancer volumes using prostate-specific antigen levels transrectal ultrasound, and systematic sextant biopsies. Urology 1995;45:75-80.
9. 9. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies: A histopathologic correlation with radical prostatectomy specimens. Cancer 1995; 75:530-8.
10. 10. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathological state in clinical stage B prostate cancer. J Urol 1989;141:341-5.
11. 11. Zinke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
12. 12. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994;152:1831-6.
13. 13. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-30.
14. 14. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-5.
15. 15. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancers by transrectal ultrasound-guided systematic biopsies. J Urol 1992;141L1076-83.
16. 16. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72: 2638-43.
17. 17. Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics-theory. [Supplement] Urology 1981;27:40-53.
18. 18. Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
19. 19. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer. Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143: 747-52.
20. 20. Eastham JA, Scardino PT. Radical prostatectomy for clinical stages T1 and T2 prostate cancer. In Comprehensive Textbook of Genitourinary Oncology. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Baltimore: Williams and Wilkins, 1996. pp 741-58.
21. 21. Murphy GP, Mettlin C, Mench H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: Results of a survey by the American College of Surgeons commission on cancer. J Urol 1994;152:1817-9.
22. 22. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. Urology 1993;42:622-9.
23. 23. Bahn DK, Lee F, Solomon MH, Gontina H, Klionsky DL, Lee FT Jr. Prostate cancer: US-guided percutaneous cryoablation. Work in progress. Radiology 1994;190:551-6.
24. 24. Lee F, Bahn DK, McHugh TA, Onik GM, Lee FT Jr. US-guided percutaneous cryoablation of prostate cancer. Radiology 1994;192:769-76.